Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine Effect on Attention, Executive Function, and Quality of Life in Veterans With Posttraumatic Stress Disorder
NCT06573970Phase 4Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Apr 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of atomoxetine in post-traumatic stress disorder (PTSD), attention deficit hyperactivity disorder (ADHD), sponsored by VA Office of Research & Development. Started Apr 2026; status: recruiting.
02
Drugs
atomoxetine
03
Conditions
post-traumatic stress disorder (PTSD)attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT06573970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06573970.